科兴制药GB19 注射液获得药物临床试验批准通知书

Core Viewpoint - The approval of clinical trials for the innovative drug "GB19 injection" by the National Medical Products Administration (NMPA) marks a significant milestone for the company in the field of monoclonal antibody research and development, particularly for autoimmune diseases [1] Group 1 - The company's wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd., received the clinical trial approval notice from the NMPA [1] - The GB19 injection targets BDCA2 (blood dendritic cell antigen 2) and represents the company's achievements based on its self-developed technology platform [1] - Successful commercialization of the GB19 injection could diversify the product offerings and enhance the company's market competitiveness [1]